Obesity is reaching epidemic proportions globally and represents a major cause of
comorbidities, mostly related to cardiovascular disease. The autonomic nervous system …

With worsening epidemiological trends for both the incidence and prevalence of type 2
diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal …

Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …

Body weight is regulated by the ability of hypothalamic neurons to orchestrate behavioral,
endocrine and autonomic responses via afferent and efferent pathways to the brainstem and …

Background and aims Chronic psychosocial stress is a risk factor for cardiovascular disease.
In view of the important role of dipeptidyl peptidase-4 (DPP-4) in human pathophysiology …

Purpose This study was aimed at the prevalence, cardiovascular risk factors of diabetic
peripheral neuropathy (DPN), and the relationship between DPN and fasting glucagon-like …

Aim Clinical use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) is consistently
associated with heart rate (HR) acceleration in type 2 diabetes patients. We explored the …

Metformin use during pregnancy is controversial and there is disparity in the acceptance of
metformin treatment in women with gestational diabetes mellitus (GDM) in Australia. Despite …

The digestive system is responsible for about 60–90% of diseases that affect humans,
making the digestive system one of the most important systems in life processes. This book …

Dipeptidyl peptidase-4 inhibitors are known to lower glucose levels and are also beneficial
in the management of cardiovascular disease. Here, we investigated whether a dipeptidyl …